News | April 08, 2021
Dr. Reddy's Laboratories launches Sapropterin Dihydrochloride powder for oral solution in US
Sapropterin dihydrochloride powder for oral solution is available in 100 mg unit dose
Sapropterin dihydrochloride powder for oral solution is available in 100 mg unit dose
Dr. Reddy's will present the safety profile of the phase 2 study, and interim data of the phase 3 study, which is expected to complete by 2pt February 2021.
Fluphenazine Hydrochloride Tablets, USP are available in 1 mg, 2.5 mg, 5 mg, and 10 mg tablets in 100 bottle count sizes.
The company has posted net profit of Rs.19.8 crores for the period ended December 31, 2020 as against net loss of Rs. 569.7 crores for the period ended December 31, 2019.
The phase 3 clinical trial of Sputnik V will be conducted on 1,500 subjects as part of the randomized, double blind, parallel group placebo controlled study in India.
The Phase 2 study of Sputnik V was conducted on 100 subjects as part of the randomized, double-blind, parallel-group, placebo-controlled study in India.
Dr Reddy’s said scheme of amalgamation was carried with adherence to all the legal requirements including tax laws
In light of the contributions of these three institutes, it was decided to organize a CSIR Startup Conclave in Hyderabad. The event, scheduled for April 22–23, 2025
Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206 and BAT2506
These appointments align with the group’s philosophy of having a strong and independent board with exceptional industry experts, ensuring strategic guidance and effective governance
Subscribe To Our Newsletter & Stay Updated
